Alerts will be sent to your verified email
Verify EmailSHILPAMED
|
Shilpa Medicare
|
Alivus Life Sciences
|
Aarti Pharmalabs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
30.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
17.0 . | n/a | n/a |
|
Number of ANDA's Filed in Europe
|
67.0 | n/a | n/a |
|
US DMF Filings
|
51.0 . | 611.0 . | n/a |
|
R&D as a % of Total Sales
|
3.76 % | 3.6 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
3.68 % | 25.27 % | 9.45 % |
|
5yr average Equity Multiplier
|
1.62 | 1.74 | 1.39 |
|
5yr Average Asset Turnover Ratio
|
0.37 | 0.71 | 0.58 |
|
5yr Avg Net Profit Margin
|
5.49 % | 20.19 % | 8.95 % |
|
Price to Book
|
3.81 | 3.82 | 3.17 |
|
P/E
|
61.94 | 22.53 | 30.31 |
|
5yr Avg Cash Conversion Cycle
|
92.76 Days | 100.66 Days | 94.46 Days |
|
Inventory Days
|
108.8 Days | 95.06 Days | 94.9 Days |
|
Days Receivable
|
118.16 Days | 132.12 Days | 94.46 Days |
|
Days Payable
|
123.42 Days | 120.47 Days | 76.47 Days |
|
5yr Average Interest Coverage Ratio
|
3.59 | 371.82 | 12.05 |
|
5yr Avg ROCE
|
5.94 % | 33.88 % | 12.13 % |
|
5yr Avg Operating Profit Margin
|
17.75 % | 29.64 % | 15.5 % |
|
5 yr average Debt to Equity
|
0.43 | 0.0 | 0.16 |
|
5yr CAGR Net Profit
|
-11.93 % | 6.67 % | n/a |
|
5yr Average Return on Assets
|
2.0 % | 14.28 % | 6.11 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
40.13 % | 74.87 % | 43.08 % |
|
Share Pledged by Promoters
|
8.73 % | 0.0 | 11.03 % |
|
Change in Promoter Holding (3 Yrs)
|
-9.88 % | -7.98 % | -2.9 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
5.15 % | 5.63 % | -4.31 % |
|
Shilpa Medicare
|
Alivus Life Sciences
|
Aarti Pharmalabs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|